MGH Hepatology Course 2019

Northampton , MA US
September 20, 2019

Join the MGH Hepatology and Transplant teams for a half day course. The care of patients with chronic liver disease is constantly advancing.  A number of new drugs have been introduced to treat chronic liver disease or will be introduced soon. This forum provides an opportunity to review how these new medications will impact treatment recommendations.

The impending changes in organ allocation will also be reviewed including how these changes will impact who should be referred for transplantation and how organs will be allocated to patients on the wait list.

Target Audience

This activity is intended for physicians, physicians, residents, fellows and allied health professionals in gastroenterology.

Learning Objectives

Upon completion of this activity, participants will be able to:

1. Interpret which patients with HBV need treatment including those patients being placed on chemotherapy and immunosuppression.
2. Recognize how to care for patients with PBC and PSC.
3. Manage patients with cirrhosis.
4. Distinguish which patients with cirrhosis should have HCV treated and the role of using HCV+ organs for transplantation.
5. Detect which patients should be referred for liver transplantation.
6. State the efforts being made to expand the donor pool for transplant and changes coming in organ allocation.

Additional Information

Provided by: 

Massachusetts General Hospital Transplant Center and Partners HealthCare System

Course summary
Available credit: 
  • 4.25 AMA PRA Category 1 Credit™
  • 4.25 Participation
Course opens: 
06/10/2019
Course expires: 
10/20/2019
Event starts: 
09/20/2019 - 11:30am
Event ends: 
09/20/2019 - 5:00pm
Cost:
$50.00

Time

Session

11:30 AM
Check-in & Lunch
12:30 PM
Greeting

Daniel S.Pratt, MD

12:35
Hepatitis B - Who to Treat and How

Karin Andersson, MD

1:00
Diagnosing and Managing Fatty Liver

Kathleen Corey, MD

1:25
Managing PBC and PSC in 2019

Daniel S. Pratt, MD

1:50
Managing Portal Hypertensive Bleeding

Irun Bhan, MD

2:15
Managing of Ascites and HRS

Michael Thiim, MD

2:40
Coffee Break
3:00
Who and When to Refer for Liver Transplantation 

Emily Bethea, MD

3:25
HCC and Transplantation

Leigh Anne Dageforde, MD

3:50
HCV - Should I Treat my Cirrhotic Patient?

Raymond Chung, MD

4:15
Expanding the Donor Pool - Use of ECD and DCD Organs

Heidi Yeh, MD

4:40
Rearranging the Donor Pool - Changes in Liver Allocation

James Markmann, MD, PhD

5:00 PM
Adjournment of Educational Activity

 

 

 

Cooley Dickinson Hospital
30 Locust Street
Northampton , MA 01061
United States

Karin Andersson, MD

Massachusetts General Hospital
Division of Gastroenterology and Hepatology


Kathleen Corey, MD

Massachusetts General Hospital
Director, MGH Fatty Liver Clinic, MGH Gastrointestinal Unit


Daniel Stephan Pratt, MD

Massachusetts General Hospital
Clinical Director, Liver Transplantation
Director, Autoimmune & Cholestatic Liver Center

Daniel S. Pratt, MD is an Assistant Professor of Medicine at Harvard Medical School, Clinical Director of Liver Transplantation, and Director of the Autoimmune and Cholestatic Liver Center at the Massachusetts General Hospital.

Dr. Pratt received his B.A. from Bowdoin College and his M.D. from the Johns Hopkins University School of Medicine.  He completed a residency in Internal Medicine and a fellowship in Gastroenterology and Hepatology at the Tufts-New England Medical Center. He served on the faculty of the Tufts University School of Medicine from 1995 until 2004. Dr. Pratt was the Medical Director of the Liver Transplant Program and Clinical Chief of the Division of Gastroenterology at the Tufts Medical Center. He joined the faculty of the Harvard Medical School and the MGH Gastrointestinal Unit in 2004. Dr. Pratt's particular area of clinical interest is autoimmune and cholestatic liver disease including autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, and IgG4 associated liver disease.He also does work in cholangiocarcinoma, hepatocellular carcinoma, viral hepatitis, and cirrhosis/endstage liver disease. Dr. Pratt is the head of the PSC Registry at MGH. Dr. Pratt has written extensively on liver disease and has been the recipient of numerous teaching awards.


Irun Bhan, MD

Massachusetts General Hospital

Irun Bhan, MD is board-certified in gastroenterology and transplant hepatology. In the clinic, he specializes in all forms of liver disease from mild to severe. His work includes the care of individuals prior to and after liver transplantation. His research interests include improving the early diagnosis of liver cancer through new technologies.


Michael Thiim, MD

Massachusetts General Hospital
Division of Gastroenterology and Hepatology


Emily D. Bethea, MD

Massachusetts General Hospital
Associate Clinical Director of Liver Transplant
Division of Gastroenterology and Hepatology
Instructor of Medicine
Harvard Medical School

Emily D. Bethea, MD is the Associate Clinical Director of Liver Transplant at Massachusetts General Hospital. She received a B.S. from the University of Wisconsin and an M.D. from the University of Chicago Pritzker School of Medicine. She completed Internal Medicine residency training at Brigham and Women’s Hospital where she stayed on for an additional invited year as a chief medical resident. She completed Gastroenterology and Hepatology fellowship followed by an Advanced Transplant Hepatology fellowship at Massachusetts General Hospital. She remains active in numerous societies and organizations, including the MGH Institute for Technology Assessment where she continues to apply simulation modeling and decision analytic methods to answer clinical questions and improve resource optimization in the areas of viral hepatitis, non-alcoholic fatty liver disease, and organ transplantation. She remains dedicated to the clinical care of patients with liver disease.


Leigh Anne Dageforde, MD

Massachusetts General Hospital
Division of Transplantation, Transplant and Hepatobiliary Surgeon

Leigh Anne Dageforde, MD, MPH is an abdominal organ transplant and hepatobiliary surgeon who specializes in the care of patients with end stage kidney and liver disease, and patients with liver and biliary cancer. She joined the Massachusetts General Hospital Transplant team in September 2018 after completing her fellowship in Abdominal Organ Transplantation and HPB surgery at Washington University in St. Louis. Dr. Dageforde completed medical school, her Master of Public Health degree and General Surgery residency at Vanderbilt University in Nashville, Tennessee.   Dr. Dageforde is also be involved in fellow, resident and student education and pursuing research in improving access to transplantation.


Raymond Chung, MD

Massachusetts General Hospital
Vice Chief, Gastrointestinal Division
Director of Hepatology and Liver Center
Medical Director, Liver Transplant Program

Dr. Raymond Chung is Medical Director of the Liver Transplant Program, Director of Hepatology and the Liver Center, Vice Chief of Gastroenterology and the Kevin and Polly Maroni Research Scholar at Massachusetts General Hospital. He has been an internationally recognized leader in HCV research in the areas of virology and pathogenesis, including hepatocarcinogenesis. He directs the NIH Cooperative Center for Human Immunology in HCV, and is co-PI of the Harvard HBV Consortium of the NIH HBV Research Network. He is PI of the MGH GI Division’s T32 Training Grant, and holds multiple NIH R01 grants and an NIH K24 Mentorship Award. He recently co-chaired the AGA-AASLD Academic Skills Workshop in 2018 and the AASLD-EASL Special Conference on HCV Elimination in 2019. He has been an Associate Editor of Hepatology, Gastroenterology, and the Journal of Infectious Diseases, and is an AE for Sleisenger and Fordtran’s Textbook of Gastroenterology and Hepatology. He is currently Senior Councilor of the American Association for the Study of Liver Diseases and will assume its presidency in 2021. He recently served as panelist and co-Chair of the AASLD/IDSA HCV Guidance panel charged with issuing treatment recommendations for hepatitis C. He has authored more than 300 original articles, reviews, and editorials.


Heidi Yeh, MD

Massachusetts General Hospital
Surgical Director, Pediatric Transplant

Heidi Yeh, MD is the Surgical Director of the Pediatric Transplant Program at Massachusetts General Hospital, and has been a member of the Massachusetts General Hospital Division of Transplant Surgery since 2007. She received her medical degree from the University of Pennsylvania School Of Medicine; she completed both her General Surgery Residency and Transplant Surgery Fellowship at the Hospital of the University of Pennsylvania and Children’s Hospital of Philadelphia.  Because her clinical practice also includes adult kidney and liver transplant patients, she has developed a special interest in the process of pediatric patients moving to adult providers and becoming independent in self-care.  Her research interests include disparities in access to transplantation care and ex vivo machine perfusion to improve organ quality.


James F. Markmann MD, PhD

Massachusetts General Hospital
Chief, Division of Transplantation
Surgical Director, Liver, Pancreas and Islet Transplant Programs
Clinical Director, MGH Transplant Center

James F. Markmann MD, PhD is the Chief of the Division of Transplant Surgery and Director of Clinical Operations at the Transplant Center at Massachusetts General Hospital, and the Claude Welch Professor of Surgery at Harvard Medical School. He specializes in liver, kidney, pancreas and islet transplantation and is the Surgical Director for the Liver and Pancreas programs. Dr. Markmann completed his MD, PhD and surgical residency training at UPenn after which he did a 2 year Transplant Surgery Fellowship at UCLA to specialize in liver transplantation. During his 11 years at MGH the number of liver transplants performed has more than doubled and the outcomes are among the best in the country.  He is active in numerous societies, editorial boards and organizations and is currently President elect for the International Pancreas and Islet Transplant Association. He has published more than 300 scientific papers over the last 30 years, most in the area of immune tolerance in liver and islet transplantation.

Partners HealthCare System is accredited by the Accreditation council for Continuing Medical Education to provide continuing medical education for physicians.

Partners HealthCare System designates this live activity for a maximum of 4.25 AMA PRA Category 1 CreditsTM . Physicians should claim only the credit commesurate with the extent of their participation in the activity.

Available Credit

  • 4.25 AMA PRA Category 1 Credit™
  • 4.25 Participation

Accreditation Period

Course opens: 
06/10/2019
Course expires: 
10/20/2019

Price

Cost:
$50.00
Please login or register to take this course.

Tuition

 

Physicians

$50

Residents, Fellows, Scientists

$25

Other Health Care Professionals

$25


Cancellation Policy:
Registrations cancelled on or before September 13, 2019 will be refunded, less a $15 administrative fee. Registrations cancelled after September 13, 2019 will not be refunded.

Contact partnerscpd@partners.org if you require assistance in cancelling your online registration.

 

Required Hardware/software

The EthosCE standard install will support the two most recent stable releases of the following browsers for all public pages, both authenticated users and anonymous: Internet Explorer, Edge, Firefox, Google Chrome, Safari, Firefox. EthosCE supports these browsers by default. Other browsers may work also; however, non-listed browsers are not officially supported.